Accordingly, vague resistance to anti-angiogenic therapy by VEGFA signaling blockade was found to be responsible for the upregulation of Ang-2 in late stage pancreatic neuroendocrine tumors [35]. The gene discussed is ANGPT2; the disease is pancreatic neuroendocrine tumor.